Mei-Chang Kuo
Fondateur chez ipharma Labs, Inc.
Profil
Mei-Chang Kuo is the founder of ipharma Labs, Inc. (founded in 2016) where he holds the title of Head-Drug Development.
He is currently working at Aerami Therapeutics, Inc. since 2010 as the Senior Vice President-Pharmaceutics.
In the past, Dr. Kuo worked at ImmuLogic Pharmaceutical Corp.
as the Director-Protein Chemistry and at Nektar Therapeutics as the Senior Director.
Dr. Kuo obtained a doctorate degree from the University of Wisconsin.
Postes actifs de Mei-Chang Kuo
| Sociétés | Poste | Début |
|---|---|---|
Aerami Therapeutics, Inc.
 Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerami Therapeutics, Inc. develops inhaled insulin products to treat diabetes patients. Its product Dance 501 is designed to produce consistently sized particles of liquid insulin in the form of a smooth mist, allowing the efficient and consistent delivery of insulin into the lungs in a few comfortable breaths. The company was founded by John Stuart Patton in February 9, 2009 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/01/2010 |
ipharma Labs, Inc.
 ipharma Labs, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Meridian Medical Technologies LLC, ipharma Labs, Inc. operates as an inhalation development contract research organization. The company is based in Union City, CA. The company was founded in 2016 by Mei-Chang Kuo, Keith Try Ung, John Patton. Keith Try Ung has been the CEO since 2016. ipharma Labs was acquired by Kindeva Drug Delivery LP, part of Meridian Medical Technologies LLC from December 12, 2022 on June 16, 2022. | Fondateur | 01/01/2016 |
Anciens postes connus de Mei-Chang Kuo
| Sociétés | Poste | Fin |
|---|---|---|
| NEKTAR THERAPEUTICS | Directeur/Membre du Conseil | - |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Corporate Officer/Principal | - |
Formation de Mei-Chang Kuo
| University of Wisconsin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| Entreprise privées | 3 |
|---|---|
ImmuLogic Pharmaceutical Corp.
ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Health Technology |
Aerami Therapeutics, Inc.
Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerami Therapeutics, Inc. develops inhaled insulin products to treat diabetes patients. Its product Dance 501 is designed to produce consistently sized particles of liquid insulin in the form of a smooth mist, allowing the efficient and consistent delivery of insulin into the lungs in a few comfortable breaths. The company was founded by John Stuart Patton in February 9, 2009 and is headquartered in Durham, NC. | Health Technology |
ipharma Labs, Inc.
ipharma Labs, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Meridian Medical Technologies LLC, ipharma Labs, Inc. operates as an inhalation development contract research organization. The company is based in Union City, CA. The company was founded in 2016 by Mei-Chang Kuo, Keith Try Ung, John Patton. Keith Try Ung has been the CEO since 2016. ipharma Labs was acquired by Kindeva Drug Delivery LP, part of Meridian Medical Technologies LLC from December 12, 2022 on June 16, 2022. | Commercial Services |
